The macrophage colony-stimulating factor 1 response signature in breast carcinoma

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 778-787

  Beck, Andrew H ^a   Espinosa, Inigo ^a   Edris, Badreddin ^a   Li, Rui ^a   Montgomery, Kelli ^a   Zhu, Shirley ^a   Varma, Sushama ^a   Marinelli, Robert J ^b   Van Rijn, Matt De ^a   West, Robert B ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; COLONY STIMULATING FACTOR 1;

ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; DESMOID TUMOR; FIBROMATOSIS; GENE IDENTIFICATION; GENE OVEREXPRESSION; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PIGMENTED VILLONODULAR SYNOVITIS; PRIORITY JOURNAL; SOLITARY FIBROUS TUMOR; TISSUE MICROARRAY;

BREAST NEOPLASMS; DATABASES AS TOPIC; GENE EXPRESSION; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; STROMAL CELLS; SURVIVAL ANALYSIS;

EID: 61349148145     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1283     Document Type: Article

References (45)

1. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
2. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
3. Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood) 2004;229:1-11.
4. Scholl SM, Pallud C, Beuvon F, et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994;86:120-6.
5. Maher MG, Sapi E,Turner B, et al. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 1998;4:1851-6.
6. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193: 727-40.
7. Aharinejad S, Paulus P, Sioud M, et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004;64:5378-84.
8. West RB,Rubin BP,Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 2006;103: 690-5.
9. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
10. Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006;8:R23.
11. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5: 607-16.
12. Pawitan Y, Bjohle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005;7: R953-64.
13. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102: 13550-5.
14. Boersma BJ, Reimers M,Yi M,et al. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008;122:1324-32.
15. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27.
16. Casey T, Bond J,Tighe S, et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat 2008.
17. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
18. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002;160:91-9.
19. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastro-intestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107-13.
20. Dennis G, Jr., Sherman BT, Hosack DA, et al. DAVID: Database forAnnotation,Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
21. von Mering C,Jensen LJ, Kuhn M, et al. STRING 7-recent developments in the integration and prediction of protein interactions. Nucleic Acids Res 2007; 35:D358-62.
22. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13:2498-504.
23. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics 2008;24:282-4.
24. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003;3:472-82.
25. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
26. Sorlie T, Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
27. Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology 2005;210:153-60.
28. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64.
29. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
30. Grage-Griebenow E, Zawatzky R, Kahlert H, Brade L, Flad H, Ernst M. Identification of a novel dendritic cell-like subset of CD64(+)/CD16(+) blood monocytes. Eur J Immunol 2001;31:48-56.
31. Goswami S, Sahai E, Wyckoff JB, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005;65: 5278-83.
32. O'Sullivan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993;342: 148-9.
33. Nielsen TO, Hsu FD, Jensen K, et al. Immunohisto-chemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
34. Lee AW, Nambirajan S, Moffat JG. CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells. Oncogene 1999;18: 7477-94.
35. Mor G, Yue W, Santen RJ, et al. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 1998;67:403-11.
36. Mor G, Sapi E, Abrahams VM, et al. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol 2003;170:114-22.
37. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
38. Tamimi RM, Brugge JS, Freedman ML, et al. Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res 2008;68:18-21.
39. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002;20:2495-9.
40. Bild AH, Potti A, Nevins JR. Linking oncogenicpathways with therapeutic opportunities. Nat Rev Cancer 2006;6:735-41.
41. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
42. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-25.
43. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071-8.
44. Allavena P, Signorelli M, Chieppa M, et al. Antiinflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65:2964-71.
45. Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006;66: 4349-56.